A balancing act: Navigating the advantages and challenges of pioneering mycetoma treatment in Sudan—A landmark trial by the Mycetoma Research Center

The global burden of mycetoma, a debilitating, neglected tropical disease, is unknown, and patients struggle to complete treatment due to limited accessibility and affordability of medications. This communication highlights a landmark clinical trial conducted by the Mycetoma Research Center (MRC) at the University of Khartoum, Sudan, in partnership with the Drugs for Neglected Diseases initiative (DNDi) and Eisai Co., Ltd. (Eisai). Published in The Lancet Infectious Diseases, this clinical trial marks a significant advancement in mycetoma research and treatment. As the first randomised clinical trial assessing a new mycetoma treatment, it compared fosravuconazole with the current standard of care, itraconazole. While the trial found no dose of fosravuconazole to be superior to itraconazole, it did reveal that fosravuconazole presented no new safety concerns. Moreover, its lower pill burden, reduced risk of drug–drug interactions, and the fact that it can be taken without food make it a more feasible alternative to the relatively expensive and less accessible itraconazole for treating eumycetoma. This clinical trial, conducted in a difficult socio-political situation in Sudan, was only made possible by the exceptional efforts of the MRC. This groundbreaking study not only advances treatment options for mycetoma but also enhances research capacity in an endemic region, paving the way for future investigations into neglected tropical diseases.